Dimethylamine

Dimethylamine

SCHEMBL3754638

CNC.CNC(C)c1nc2ccc([N+](=O)[O-])c(C)c2s1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.41
ALDH1A1 P00352 3/20 0.41
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
POLB P06746 2/20 0.37
TDP1 Q9NUW8 1/20 0.35
HPGD P15428 1/20 0.34
GALR2 O43603 1/20 0.33
LMNA P02545 1/20 0.33
BRD4 O60885 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HTT P42858 2/20 0.33
TSHR P16473 1/20 0.33
GLA P06280 1/20 0.32
CTSB P07858 1/20 0.32
CTSH P09668 1/20 0.32
ACP1 P24666 1/20 0.32
GAA P10253 1/20 0.32
DYRK1A Q13627 1/20 0.31
TXNRD1 Q16881 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3750501 0.74 ALDH1A1 (0.72) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL3748576 0.74 MAPT (0.48) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL4743474 0.73 MAPT (0.44) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL27566824 0.71 KMT2A (0.53) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL27697763 0.68 MAPT (0.40) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL6068173 0.68 RAB9A (0.53) ALDH1A1MEN1KMT2APOLBSMN1; SMN2
SCHEMBL5306398 0.66 ALDH1A1 (0.40) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL6784487 0.64 ATIC (0.46) MAPTALDH1A1MEN1KMT2ATDP1
SCHEMBL9719281 0.62 TDP1 (0.71) MAPTALDH1A1TDP1LMNASMN1; SMN2
SCHEMBL30503599 0.62 TDP1 (0.71) MAPTALDH1A1TDP1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7838543-B2 Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles ELI LILLY AND COMPANY (US) 2010-11-23 US disclosed
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R MAPT 1507/4885ALDH1A1 1529/4885MEN1 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.